Status: Completed
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable

Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any acute demyelinating lesion of the optic nerve (primary form of CON, P-CON). In both S-CON and P-CON, a long term progressive ganglion cell axonal loss occurs. This axonal damage could be secondary to retrograde atrophy of axons within plaques of demyelination or a primary progressive degeneration of ganglion cells, but the underlying physiopathology has not been fully questioned in the different profile types of CON. In this project, investigators aim at understanding the pathophysiology of S-CON and P-CON, i.e. secondary to demyelination or primary degeneration, in patients complaining of persistent visual complaints. In a first cross sectional study, 30 MS patients with mild to moderate P-CPON or S-CON and 30 age-matched control subjects will perform an extensive neuro-ophthalmological assessment including clinical examination, visual evoked potentials (pattern and low contrast), electroretinogram (pattern and multifocal ERG), OCT (peripapillary and macular volume scan segmentation protocols) and MRI of the optic nerve. In these patients with mild to moderate CON, investigators aim at differentiating patients showing predominant demyelination from those showing pure or predominant axonal degeneration. Visual function assessment and degree of axonal degeneration will be compared and correlated in the two types of underlying pathophysiology and in the group of control subject. In a following longitudinal study, the patients will be re-assessed a year later in order to evaluate the progression of CON in both profile types. Our hypothesis would be that visual function and progression is worse in the degeneration group as compared to the demyelination group. This study should help to find reliable measures of the pathophysiology of CON and correlate it with the long-term visual prognostic of the disease.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: Accepts Healthy Volunteers

⁃ All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria (2010).

⁃ All patients may present a chronic visual complaint.

⁃ All patients may present mild to moderate chronic optic neuropathy (cf infra)

⁃ All patients may not have recent acute optic neuritis (<2 years)

⁃ All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee.

⁃ Age: > 18

⁃ Able to understand the instructions

⁃ Having a health coverage

⁃ Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic neuropathy

⁃ For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria:

⁃ Far Visual Acuity (ETDRS charts, 100% contrast) < 85 letters

⁃ Mean visual field defect on static perimetry> 2dB

⁃ Mean pRNFL in OCT < 80 µ.

⁃ Color vision score > 35

⁃ Disc pallor Diagnosis of mild to moderate optic neuropathy

⁃ Far Visual Acuity (ETDRS charts, 100% contrast) >70 letters Diagnosis of chronic optic neuropathy

⁃ Stable or worsening of visual acuity, visual field and/or RNFL in OCT, at 6 month of interval

• Inclusion criteria for controls

⁃ Age > 18 years

⁃ Visual acuity score (ETDRS) > 85

⁃ Able to understand the instructions

⁃ Having a health coverage

⁃ Informed and consenting to give his written consent

Other Locations
Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON
Time Frame
Start Date: September 2014
Completion Date: August 2016
Target number of participants: 39
Other: patients
patients with chronic optic neuropathy in multiple sclerosis
Other: Controls
healthy volunteers
Leads: Hospices Civils de Lyon
Collaborators: Fondation pour la Recherche Médicale

This content was sourced from

Similar Clinical Trials